Ketamine has rapid and profound effects in treating depression - with a novel mechanism of action. Intranasal ketamine was recently approved by the FDA for treatment-resistant depression.
Does this anaesthetic agent hold new hope for treating depression and even suicidality?
This talk will detail the neuroscience mechanisms underlying ketamine's action on the brain as well as showcase groundbreaking clinical research undertaken both within the School and internationally.
Colleen Loo is a clinical psychiatrist and Professor in Psychiatry at UNSW. Her research focuses on novel treatments for depression. She has led research in the use of ketamine to treat depression in Australia, including early trials examining different methods of giving ketamine, dose-response relationships and the first randomised controlled trial in older depressed patients.
Adam Bayes is a consultant psychiatrist and clinical senior lecturer at the School of Psychiatry, UNSW. Post PhD, one of his key research interests includes investigating novel treatments for mood disorders. He is currently involved in two ketamine-related clinical trials and runs a specialist ketamine treatment program at BDI.